首页> 外文期刊>Therapeutic advances in respiratory disease. >Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study
【24h】

Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study

机译:合生元补充剂预防儿童常见冬季疾病的功效:一项随机,双盲,安慰剂对照的先导研究

获取原文
           

摘要

Background and aims: The purpose of this study was to investigate the efficacy of a synbiotic supplementation in reducing common winter diseases in children.Methods: A randomized, double-blind, placebo-controlled, multicentre study was conducted in young school-age children (3—7 years old) during a winter period. Participants were otherwise healthy children who suffered from at least three episodes of ear, nose and throat (ENT), respiratory tract or gastrointestinal illness during the previous winter. They were supplemented daily with either a synbiotic preparation (Lactobacillus helveticus R0052, Bifidobacterium infantis R0033, Bifidobacterium bifidum R0071, and fructooligosaccharide) or a matched placebo for 3 months. Over this period, all emergent health episodes of any type were recorded by parents in a diary. They were checked by investigators at regular monthly visits. The main study outcome was the percentage of children free of any episode during the study course.Results: We randomized 135 children (mean age: 4.1±1.0 years) to the synbiotic group (n = 62) or placebo (n = 73) group. At least one illness episode was reported in 32 children in the synbiotic group and 50 in the placebo group (51.6% versus 68.5%). This corresponded to a significant 25% relative risk reduction (95% CI 0.6—44.3%; p = 0.045). This difference was due to a decrease in the number of children who suffered from at least one ENT, respiratory tract or gastrointestinal disorder (50.0% with synbiotic versus 67.1% with placebo; p = 0.044). At least one sickness school day loss was noted in 25.8% of children with the synbiotic as compared with 42.5% with placebo (p = 0.043). No treatment related side effects were detected in either group.Conclusions: This study suggests that a 3-month supplementation with this synbiotic preparation can decrease the risk of occurrence of common infectious diseases in children and limits the risk of school day loss.
机译:背景与目的:本研究的目的是研究一种合生素补充剂在减少儿童常见冬季疾病中的功效。方法:对学龄儿童进行一项随机,双盲,安慰剂对照,多中心研究( 3-7岁)在冬季。参加者是其他健康儿童,他们在上一个冬天至少经历了三次耳,鼻,喉(ENT)发作,呼吸道或胃肠道疾病。每天用合生素制剂(瑞士乳杆菌R0052,婴儿双歧杆菌R0033,双歧双歧杆菌R0071和低聚果糖)或匹配的安慰剂补充3个月。在此期间,父母会在日记中记录任何类型的所有突发健康事件。研究人员在每月一次的定期访问中对它们进行了检查。主要研究结果为研究过程中无任何发作的儿童百分比。结果:我们将135名儿童(平均年龄:4.1±1.0岁)随机分为合生元组(n = 62)或安慰剂组(n = 73) 。据报道,合生元组的32名儿童和安慰剂组的50名儿童至少发生了一次疾病发作(51.6%对68.5%)。这对应于显着降低25%的相对风险(95%CI 0.6-44.3%; p = 0.045)。这种差异是由于患有至少一种耳鼻喉,呼吸道或胃肠道疾病的儿童人数减少(合生素为50.0%,安慰剂为67.1%; p = 0.044)。患有该合生素的儿童中至少有1个疾病的学校放假时间为25.8%,而使用安慰剂的儿童为42.5%(p = 0.043)。两组均未发现与治疗相关的副作用。结论:这项研究表明,使用这种合生元制剂补充3个月可以降低儿童发生常见传染病的风险,并减少失学日的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号